Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-102 Long-term Extension in Angelman Syndrome
NCT06415344Phase 3Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
A Phase 3 trial of apazunersen in Angelman syndrome (AS), sponsored by Ultragenyx Pharmaceutical Inc.. Started Jul 2024; status: terminated.
02
Drugs
apazunersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT06415344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415344.